JP2016528914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528914A5 JP2016528914A5 JP2016537848A JP2016537848A JP2016528914A5 JP 2016528914 A5 JP2016528914 A5 JP 2016528914A5 JP 2016537848 A JP2016537848 A JP 2016537848A JP 2016537848 A JP2016537848 A JP 2016537848A JP 2016528914 A5 JP2016528914 A5 JP 2016528914A5
- Authority
- JP
- Japan
- Prior art keywords
- activity profile
- panel
- subject
- genetic markers
- multikinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 70
- 230000002068 genetic effect Effects 0.000 claims description 36
- 229940124303 multikinase inhibitor Drugs 0.000 claims description 34
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 24
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 24
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 16
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 16
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 13
- 102100026656 Actin, alpha skeletal muscle Human genes 0.000 claims description 13
- 102000058080 Glucose Transporter Type 5 Human genes 0.000 claims description 13
- 101001066181 Homo sapiens 6-phosphogluconolactonase Proteins 0.000 claims description 13
- 101000834207 Homo sapiens Actin, alpha skeletal muscle Proteins 0.000 claims description 13
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims description 13
- 101001093919 Homo sapiens SEC14-like protein 2 Proteins 0.000 claims description 13
- 101000763474 Homo sapiens Transmembrane protein 140 Proteins 0.000 claims description 13
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims description 13
- 102100035174 SEC14-like protein 2 Human genes 0.000 claims description 13
- 108091006301 SLC2A5 Proteins 0.000 claims description 13
- 102000004265 STAT2 Transcription Factor Human genes 0.000 claims description 13
- 108010081691 STAT2 Transcription Factor Proteins 0.000 claims description 13
- 102100027030 Transmembrane protein 140 Human genes 0.000 claims description 13
- 102100040215 UDP-glucuronosyltransferase 2A1 Human genes 0.000 claims description 13
- 101710199217 UDP-glucuronosyltransferase 2A1 Proteins 0.000 claims description 13
- 108091000080 Phosphotransferase Proteins 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 102000020233 phosphotransferase Human genes 0.000 claims description 8
- 102000009929 raf Kinases Human genes 0.000 claims description 8
- 108010077182 raf Kinases Proteins 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 2
- 229960003005 axitinib Drugs 0.000 claims description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
- 229960001292 cabozantinib Drugs 0.000 claims description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 230000004952 protein activity Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000000034 method Methods 0.000 description 21
- 238000002493 microarray Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/082487 | 2013-08-28 | ||
| CN2013082487 | 2013-08-28 | ||
| PCT/US2014/053142 WO2015031604A1 (en) | 2013-08-28 | 2014-08-28 | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528914A JP2016528914A (ja) | 2016-09-23 |
| JP2016528914A5 true JP2016528914A5 (enExample) | 2017-09-28 |
| JP6612232B2 JP6612232B2 (ja) | 2019-11-27 |
Family
ID=52587328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537848A Active JP6612232B2 (ja) | 2013-08-28 | 2014-08-28 | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11136625B2 (enExample) |
| EP (1) | EP3039424B1 (enExample) |
| JP (1) | JP6612232B2 (enExample) |
| CN (1) | CN105659085B (enExample) |
| CY (1) | CY1123415T1 (enExample) |
| DK (1) | DK3039424T3 (enExample) |
| ES (1) | ES2813877T3 (enExample) |
| PT (1) | PT3039424T (enExample) |
| WO (1) | WO2015031604A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6612232B2 (ja) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド（タイカン） | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
| WO2017110764A1 (ja) * | 2015-12-24 | 2017-06-29 | 公益財団法人がん研究会 | マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー |
| WO2020085936A1 (ru) * | 2018-10-24 | 2020-04-30 | Общество С Ограниченной Ответственностью "Онкобокс" | Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки |
| JP2022517563A (ja) * | 2019-01-02 | 2022-03-09 | チョーチアン クラウンマブ バイオテック カンパニー リミテッド | タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置 |
| CN111521810B (zh) * | 2019-02-02 | 2024-06-21 | 中国科学院上海药物研究所 | 癌症患者根据脾酪氨酸激酶进行分层 |
| CN111693707A (zh) * | 2020-07-16 | 2020-09-22 | 首都医科大学附属北京朝阳医院 | Rock激酶活性在辅助诊断血管炎患者中的应用 |
| CN118345086B (zh) * | 2024-04-22 | 2024-10-11 | 西部(重庆)科学城种质创制大科学中心 | 柑橘溃疡病抗性Cs7g24050基因及其编码蛋白与应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5871928A (en) | 1989-06-07 | 1999-02-16 | Fodor; Stephen P. A. | Methods for nucleic acid analysis |
| US5677195A (en) | 1991-11-22 | 1997-10-14 | Affymax Technologies N.V. | Combinatorial strategies for polymer synthesis |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| CN100376567C (zh) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
| JP5004392B2 (ja) | 1999-12-22 | 2012-08-22 | スージェン， インク． | インドリノン化合物を用いてｃ−ｋｉｔチロシン蛋白質キナーゼ機能を調節する方法 |
| AR034118A1 (es) | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
| ES2556946T3 (es) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pirimidinaminas como moduladores de la angiogénesis |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU2002351196A1 (en) | 2001-12-03 | 2003-06-17 | Bayer Pharmaceuticals Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| SE0104164L (sv) | 2001-12-11 | 2003-06-12 | Ericsson Telefon Ab L M | Högspännings-mos-transistor |
| NO317200B1 (no) | 2002-08-09 | 2004-09-13 | Best Practice Deployment As | System for trafikkopplaering i et kjoretoy |
| EP1539813A2 (en) | 2002-09-27 | 2005-06-15 | ORIDIS BIOMED Forschungs- und Entwicklungs GmbH | Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| CA2528669A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| GB0411378D0 (en) | 2004-05-21 | 2004-06-23 | Astrazeneca Ab | Pharmaceutical compositions |
| US20070105133A1 (en) * | 2005-06-13 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1946115A4 (en) | 2005-10-21 | 2009-12-02 | Bayer Healthcare Llc | METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY |
| US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| JP2009513706A (ja) | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ソラフェニブを用いた癌の治療 |
| CA2657379A1 (en) | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
| EP2074226A2 (en) * | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| AU2008279027B8 (en) * | 2007-07-25 | 2014-03-06 | Eisai R & D Management Co., Ltd. | Multikinase inhibitors for use in the treatment of cancer |
| US20090062368A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched sunitinib |
| US20090062347A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched axitinib |
| KR101553211B1 (ko) | 2007-09-10 | 2015-09-15 | 씨아이피엘에이 엘티디. | Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체 |
| CN101939425B (zh) | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
| WO2009054004A2 (en) | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
| EP2220072A2 (en) | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| US20100256392A1 (en) | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| US20110112164A1 (en) | 2008-02-21 | 2011-05-12 | Generics (Uk) Limited | Novel polymorphs and processes for their preparation |
| WO2009106825A1 (en) | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
| EP2098521A1 (en) | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
| EP2142507A1 (en) | 2008-03-06 | 2010-01-13 | Sicor, Inc. | Process for the preparation of sorafenib and salts thereof |
| PL2274303T3 (pl) | 2008-03-31 | 2013-03-29 | Teva Pharma | Sposoby otrzymywania sunitynibu i jego soli |
| EP2313396A1 (en) | 2008-06-23 | 2011-04-27 | Natco Pharma Limited | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt |
| CA2731605A1 (en) | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| WO2010036796A1 (en) | 2008-09-26 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Pyridineamine derivatives |
| CA2704448A1 (en) | 2008-09-30 | 2010-04-08 | Teva Pharmaceutical Industries Ltd. | Amorphous compositions of sunitinib base and l-malic acid |
| CA2741087A1 (en) | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
| EP2181991A1 (en) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| US10262103B2 (en) * | 2008-11-18 | 2019-04-16 | Raphael LEHRER | Individualized cancer treatment |
| WO2010135608A1 (en) | 2009-05-20 | 2010-11-25 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
| CN102573477A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素惠尔康制造业私人有限公司 | 治疗方法 |
| US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| JP2013505968A (ja) | 2009-10-01 | 2013-02-21 | シーエスエル、リミテッド | フィラデルフィア染色体陽性白血病の治療方法 |
| WO2011047019A1 (en) | 2009-10-13 | 2011-04-21 | Yale University | An objective, quantitative method to predict histological subtype in non-small cell lung cancer |
| JP2013508396A (ja) | 2009-10-23 | 2013-03-07 | グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド | 組成物および方法 |
| UY33164A (es) | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
| WO2011104555A2 (en) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
| WO2011128699A2 (en) | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
| AR081364A1 (es) | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| WO2011146458A1 (en) | 2010-05-18 | 2011-11-24 | Glaxo Wellcome Manufacturing Pte Ltd | Method of administration and treatment |
| AU2010363613B2 (en) | 2010-11-01 | 2015-02-05 | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. | Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles |
| US9150547B2 (en) | 2010-11-29 | 2015-10-06 | Hetero Research Foundation | Process for the preparation of pazopanib using novel intermediate |
| US10220020B2 (en) | 2010-12-23 | 2019-03-05 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
| WO2012103060A1 (en) | 2011-01-27 | 2012-08-02 | Glaxo Wellcome Manufacturing Pte Ltd | Method of administration and treatment |
| WO2012116040A1 (en) * | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| CN102283836B (zh) * | 2011-06-27 | 2013-01-09 | 苏州大学附属第一医院 | 索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用 |
| CA2840491A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sorafenib |
| KR20140067001A (ko) * | 2011-08-08 | 2014-06-03 | 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. | 생물지표 조성물 및 방법 |
| US20140248372A1 (en) | 2011-09-19 | 2014-09-04 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
| TW201328725A (zh) | 2011-09-30 | 2013-07-16 | Pfizer | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 |
| WO2013090419A1 (en) | 2011-12-12 | 2013-06-20 | Stc.Unm | Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia |
| WO2013138522A2 (en) * | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| JP6612232B2 (ja) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド（タイカン） | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
-
2014
- 2014-08-28 JP JP2016537848A patent/JP6612232B2/ja active Active
- 2014-08-28 PT PT148409444T patent/PT3039424T/pt unknown
- 2014-08-28 WO PCT/US2014/053142 patent/WO2015031604A1/en not_active Ceased
- 2014-08-28 CN CN201480057475.2A patent/CN105659085B/zh active Active
- 2014-08-28 DK DK14840944.4T patent/DK3039424T3/da active
- 2014-08-28 EP EP14840944.4A patent/EP3039424B1/en active Active
- 2014-08-28 US US14/915,121 patent/US11136625B2/en active Active
- 2014-08-28 ES ES14840944T patent/ES2813877T3/es active Active
-
2020
- 2020-08-28 CY CY20201100811T patent/CY1123415T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | The mechanisms of HBV-induced hepatocellular carcinoma | |
| Fan et al. | A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma | |
| Ma et al. | Avian influenza A virus H5N1 causes autophagy-mediated cell death through suppression of mTOR signaling | |
| JP2016519763A5 (enExample) | ||
| López-Alonso et al. | Impairment of autophagy decreases ventilator-induced lung injury by blockade of the NF-κB pathway | |
| NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
| Lee et al. | Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection | |
| JP2014531213A5 (enExample) | ||
| JP2016536303A5 (enExample) | ||
| HK1259386A1 (zh) | 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途 | |
| NZ712823A (en) | Molecular diagnostic test for cancer | |
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| BR112012010114A2 (pt) | domínio variável único de imunoglobulina, ligante multiespecífico, antagonista, uso do antagonista, método para tratamento e/ou profilaxia de uma condição inflamatória em um paciente, ácido nucleico, vetor, e, célula hospedeira. | |
| Janiak et al. | TIMP4 expression is regulated by miR‐200b‐3p in prostate cancer cells | |
| JP2015530094A5 (enExample) | ||
| MX2014000204A (es) | Metodo de administracion y tratamiento. | |
| JP2010527375A5 (enExample) | ||
| JP2017513515A5 (enExample) | ||
| JP2016510591A5 (enExample) | ||
| JP2015513901A5 (enExample) | ||
| JP2016531843A5 (enExample) | ||
| Mahmutovic-Persson et al. | Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNβ production in diseased bronchial epithelial cells | |
| JP2017525955A5 (enExample) | ||
| RU2017106891A (ru) | Биомаркеры поликистозной болезни почек и пути их применения | |
| JP2016123339A (ja) | 多能性幹細胞の品質診断方法及び診断キット、抗がん剤並びに疾患モデル動物 |